search icon
coep-img

Coeptis Therapeutics Inc, Common Stock

COEP

NAQ

$8.24

+$0.24

(3%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$16.94M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
44.43K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.94
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.31 L
$13.58 H
$8.24

About Coeptis Therapeutics Inc, Common Stock

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology. The company is also developing a multi-antigen CAR T technology licensed from the University of Pittsburgh, and the GEAR cell therapy and companion diagnostic platforms, which are developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCOEPSectorS&P500
1-Week Return22.07%0.31%-1.26%
1-Month Return115.71%0.6%-4.16%
3-Month Return101.96%-9.44%-0.46%
6-Month Return37.33%-5.15%3.58%
1-Year Return-29.09%0.33%22.47%
3-Year Return-95.88%4.53%25.13%
5-Year Return-95.84%35.98%77.7%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue30.76K75.00K---[{"date":"2020-12-31","value":41.01,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue964.22K447.41K1.00M1.00M1.00M[{"date":"2020-12-31","value":96.29,"profit":true},{"date":"2021-12-31","value":44.68,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":99.99,"profit":true}]
Gross Profit(933.46K)(372.41K)(1.00M)(1.00M)(1.00M)[{"date":"2020-12-31","value":-93345600,"profit":false},{"date":"2021-12-31","value":-37241300,"profit":false},{"date":"2022-12-31","value":-100138400,"profit":false},{"date":"2023-12-31","value":-100138400,"profit":false},{"date":"2024-12-31","value":-100123600,"profit":false}]
Gross Margin(3034.54%)(496.55%)(Infinity%)(Infinity%)-[{"date":"2020-12-31","value":-3034.54,"profit":false},{"date":"2021-12-31","value":-496.55,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses5.78M14.12M34.20M34.20M20.49M[{"date":"2020-12-31","value":16.9,"profit":true},{"date":"2021-12-31","value":41.29,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":59.92,"profit":true}]
Operating Income(6.86M)(14.05M)(34.20M)(34.20M)(21.49M)[{"date":"2020-12-31","value":-686140300,"profit":false},{"date":"2021-12-31","value":-1404593200,"profit":false},{"date":"2022-12-31","value":-3419596400,"profit":false},{"date":"2023-12-31","value":-3419596400,"profit":false},{"date":"2024-12-31","value":-2149112500,"profit":false}]
Total Non-Operating Income/Expense(2.44M)409.52K(3.60M)(3.51M)-[{"date":"2020-12-31","value":-596.57,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-878.27,"profit":false},{"date":"2023-12-31","value":-858.19,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(9.16M)(13.45M)(37.57M)(37.57M)(21.27M)[{"date":"2020-12-31","value":-915628600,"profit":false},{"date":"2021-12-31","value":-1344928000,"profit":false},{"date":"2022-12-31","value":-3757421700,"profit":false},{"date":"2023-12-31","value":-3757421700,"profit":false},{"date":"2024-12-31","value":-2126653700,"profit":false}]
Income Taxes(2.15M)972.92K3.39M3.39M-[{"date":"2020-12-31","value":-63.26,"profit":false},{"date":"2021-12-31","value":28.67,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(7.01M)(14.42M)(40.97M)(40.97M)-[{"date":"2020-12-31","value":-700959500,"profit":false},{"date":"2021-12-31","value":-1442219900,"profit":false},{"date":"2022-12-31","value":-4096775900,"profit":false},{"date":"2023-12-31","value":-4096775900,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(9.16M)(13.45M)(37.57M)(20.19M)-[{"date":"2020-12-31","value":-915628600,"profit":false},{"date":"2021-12-31","value":-1344928000,"profit":false},{"date":"2022-12-31","value":-3757421700,"profit":false},{"date":"2023-12-31","value":-2018516000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(7.01M)(14.42M)(40.97M)(40.97M)(21.27M)[{"date":"2020-12-31","value":-700959500,"profit":false},{"date":"2021-12-31","value":-1442219900,"profit":false},{"date":"2022-12-31","value":-4096775900,"profit":false},{"date":"2023-12-31","value":-4096775900,"profit":false},{"date":"2024-12-31","value":-2126653700,"profit":false}]
EPS (Diluted)(0.44)(0.41)(3.41)(0.87)-[{"date":"2020-12-31","value":-43.81,"profit":false},{"date":"2021-12-31","value":-41,"profit":false},{"date":"2022-12-31","value":-340.96,"profit":false},{"date":"2023-12-31","value":-87.27,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

COEP
Cash Ratio 0.33
Current Ratio 0.40

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

COEP
ROA (LTM) -187.35%
ROE (LTM) -1481.29%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

COEP
Debt Ratio Lower is generally better. Negative is bad. 0.44
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.54

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

COEP
Trailing PE NM
Forward PE NM
P/S (TTM) 45.68
P/B 3.51
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Coeptis Therapeutics Inc share price today?

Coeptis Therapeutics Inc (COEP) share price today is $8.24

Can Indians buy Coeptis Therapeutics Inc shares?

Yes, Indians can buy shares of Coeptis Therapeutics Inc (COEP) on Vested. To buy Coeptis Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in COEP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Coeptis Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Coeptis Therapeutics Inc (COEP) via the Vested app. You can start investing in Coeptis Therapeutics Inc (COEP) with a minimum investment of $1.

How to invest in Coeptis Therapeutics Inc shares from India?

You can invest in shares of Coeptis Therapeutics Inc (COEP) via Vested in three simple steps:

  • Click on Sign Up or Invest in COEP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Coeptis Therapeutics Inc shares
What is Coeptis Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Coeptis Therapeutics Inc (COEP) is $13.58. The 52-week low price of Coeptis Therapeutics Inc (COEP) is $2.31.

What is Coeptis Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Coeptis Therapeutics Inc (COEP) is

What is Coeptis Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Coeptis Therapeutics Inc (COEP) is 3.51

What is Coeptis Therapeutics Inc dividend yield?

The dividend yield of Coeptis Therapeutics Inc (COEP) is 0.00%

What is the Market Cap of Coeptis Therapeutics Inc?

The market capitalization of Coeptis Therapeutics Inc (COEP) is $16.94M

What is Coeptis Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Coeptis Therapeutics Inc is COEP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top